Understanding the Current Rating
The Strong Sell rating indicates that the stock is considered to have significant risks and challenges that outweigh potential rewards at this time. Investors are advised to exercise caution and consider the underlying factors contributing to this assessment before making investment decisions. The rating reflects a comprehensive evaluation of four key parameters: Quality, Valuation, Financial Trend, and Technicals.
Quality Assessment
As of 12 May 2026, Sun Pharma Advanced Research Company Ltd’s quality grade is assessed as below average. This is primarily due to weak long-term fundamental strength. The company reports a negative book value, signalling that liabilities exceed assets on its balance sheet, which is a red flag for financial stability. Over the past five years, net sales have declined at an annualised rate of -26.49%, while operating profit has stagnated at 0%. Such trends suggest that the company has struggled to generate sustainable growth and profitability, undermining its overall quality rating.
Valuation Considerations
The valuation grade for the stock is currently deemed risky. Despite the stock generating a positive return of 10.95% over the past year, the company’s financial health raises concerns. Negative EBITDA of ₹-227.62 crores and a negative net sales growth of -43.29% in the latest six months highlight operational difficulties. The stock trades at valuations that are considered elevated relative to its historical averages, increasing the risk profile for investors. This risky valuation suggests that the market may be pricing in expectations that are not fully supported by the company’s fundamentals.
Financial Trend Analysis
The financial trend is rated as very negative. The latest data shows that net sales for the most recent six months stand at ₹16.31 crores, reflecting a decline of -41.27%. Profit after tax (PAT) is deeply negative at ₹-143.91 crores, also down by -41.27%. Meanwhile, interest expenses have surged by 51.91% to ₹16.30 crores, indicating rising financial burdens. The company has reported negative results for three consecutive quarters, underscoring ongoing operational and financial challenges. Furthermore, the EBIT to interest coverage ratio averages at a concerning -141.22, signalling a weak ability to service debt obligations.
Technical Outlook
Technically, the stock is graded as mildly bullish. Despite fundamental weaknesses, the stock price has shown some resilience, with a 6-month return of +23.32% and a year-to-date gain of +22.13%. The short-term price momentum suggests some investor interest and potential for recovery, but this is tempered by the underlying financial risks. The one-day price change of -2.55% reflects recent volatility, which investors should monitor closely.
Stock Performance Summary
As of 12 May 2026, the stock’s returns are mixed across different time frames. While the 1-day return is negative at -2.55%, the 1-week and 1-month returns are positive at +17.24% and +10.83% respectively. Over three and six months, the stock has gained +21.67% and +23.32%. The year-to-date return stands at +22.13%, and the 1-year return is +10.95%. These figures indicate that despite fundamental challenges, the stock has experienced some price appreciation, likely driven by market sentiment or sector-specific factors.
Implications for Investors
The Strong Sell rating suggests that investors should approach Sun Pharma Advanced Research Company Ltd with caution. The company’s weak fundamentals, risky valuation, and very negative financial trends outweigh the mildly bullish technical signals. Investors seeking stability and growth in the Pharmaceuticals & Biotechnology sector may find better opportunities elsewhere. Those holding the stock should carefully evaluate their risk tolerance and consider the potential for further downside given the company’s current financial health.
Our current monthly pick, this Mid Cap from Automobile Two & Three Wheelers, survived rigorous evaluation against dozens of contenders. See why experts are backing this one!
- - Rigorous evaluation cleared
- - Expert-backed selection
- - Mid Cap conviction pick
Company Profile and Market Context
Sun Pharma Advanced Research Company Ltd is classified as a small-cap entity within the Pharmaceuticals & Biotechnology sector. The company’s market capitalisation reflects its relatively modest size compared to larger industry peers. The Mojo Score currently stands at 22.0, down from 31 prior to the rating update on 01 Feb 2024, reinforcing the Strong Sell grade. This score encapsulates the combined assessment of quality, valuation, financial trend, and technical factors.
Long-Term Growth Challenges
The company’s long-term growth prospects appear constrained. Negative book value and declining net sales over five years highlight structural issues. Operating profit has remained flat, indicating an inability to improve operational efficiency or expand margins. The weak EBIT to interest coverage ratio further emphasises financial stress, raising concerns about the company’s capacity to meet debt obligations without additional capital or restructuring.
Recent Financial Results
The latest six-month results reveal a sharp contraction in sales and profitability. Net sales at ₹16.31 crores have fallen by over 40%, while losses have deepened with PAT at ₹-143.91 crores. Rising interest costs exacerbate the financial strain, with a 51.91% increase in interest expenses. These trends have persisted for three consecutive quarters, signalling ongoing operational difficulties and a challenging business environment.
Stock Price Volatility and Market Sentiment
Despite fundamental weaknesses, the stock has shown some price strength in recent months, with returns exceeding 20% over six months and year-to-date. This divergence between price performance and fundamentals may reflect speculative trading, sector rotation, or anticipation of potential turnaround catalysts. However, the mildly bullish technical grade advises caution, as the underlying financial risks remain significant.
Conclusion
Sun Pharma Advanced Research Company Ltd’s Strong Sell rating by MarketsMOJO is grounded in its below-average quality, risky valuation, very negative financial trends, and only mildly bullish technical outlook. Investors should carefully weigh these factors against their investment objectives and risk appetite. The company’s current financial challenges and valuation risks suggest that it is not a favourable investment at this time, despite some recent positive price movements.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
